A Phase 1a/1b Trial in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma to Determine theSafety Profile, Pharmacology, and Maximum Tolerated Dose of ST-001, a fenretinide phospholipidsuspension (12.5 mg/mL) for Intravenous Infusion
Study of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma
Sponsor: SciTech Development, LLC
Enrolling: Male and Female Patients
IRB Number: AAAU7936
U.S. Govt. ID: NCT04234048
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this study is to see what effects, good and/or bad, the study drug, ST-001, has on you and your cancer, to find the best dose for treating your condition, and to see how safe ST-001 is for participants with your condition. This study will help us understand more about whether intravenous (injected into the vein) ST-001, will be a useful study treatment for subjects with Relapsed/Refractory T-cell Non-Hodgkin Lymphoma (T-Cell NHL). Relapsed or refractory disease means your disease that has come back after initial treatment or did not respond to initial treatment. Approximately 46 patients will be enrolled across 5-10 clinical sites nationwide. ST-001 has not been studied in human clinical trials yet.
Investigator
Barbara Pro, MD
Do You Qualify?
Are you at least 18 years of age or older? Yes No
Do you have relapsed or refractory disease after at least two prior systemic drug treatment regimens? Yes No
Are you willing to come into the clinic for additional evaluations and treatment? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder


CAPTCHA
Image CAPTCHA
Enter the characters shown in the image.
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Cancel
For more information, please contact:
Research Nurse Navigator
cancerclinicaltrials@cumc.columbia.edu
212-342-5162
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE